Table 2. The impact of viral characteristics in both tumour and non-neoplastic liver tissue (NT) on overall survival and HCC recurrence.
|
Overall survival |
Recurrence |
|||
|---|---|---|---|---|
| Death events (5 years) | Pa | Recurrence events (5 years) | P-valuea | |
|
HBV DNA | ||||
| Tumour | ||||
| Low (n=49)b | 8 | 0.4 | 14 | 0.2 |
| High (n=50) | 8 | 21 | ||
| NT | ||||
| Low (n=49) | 7 | 0.5 | 16 | 0.7 |
| High (n=50) | 9 | 19 | ||
|
cccDNA | ||||
| Tumour | ||||
| Low (n=49) | 9 | 0.4 | 16 | 0.2 |
| High (n=50) | 7 | 19 | ||
| NT | ||||
| Low (n=49) | 8 | 0.4 | 20 | 0.8 |
| High (n=50) | 8 | 15 | ||
|
Replicative activityc | ||||
| Tumour | ||||
| Low (n=43) | 5 | 0.2 | 15 | 0.6 |
| High (n=43) | 10 | 15 | ||
| NT | ||||
| Low (n=48) | 6 | 0.1 | 12 | 0.04 |
| High (n=48) | 10 | 21 | ||
Abbreviations: cccDNA=covalently closed circular DNA; HBV=hepatitis B virus; HCC=hepatocellular carcinoma; NT=non-neoplastic liver tissue.
Number of death or recurrence events are listed in the table, and the P-value was determined by Kaplan–Meier analysis and Wilcoxon test or log-rank test. P<0.05 were indicated in bold.
a
P-value determined by Kaplan–Meier analysis and Wilcoxon test or log-rank test.
b
Groups were separated according to median cutoff values.
c
Replicative activity was evaluated by the cccDNA/HBV DNA ratio. This ratio was not available in patients with undetectable HBV DNA.